Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase | Zendy

Anusha Seneviratne | Zendy; Luke Cave | Zendy; Gareth Hyde | Zendy; Søren K. Moestrup | Zendy; David Carling | Zendy; Justin C. Mason | Zendy; Dorian O. Haskard | Zendy; Joseph J. Boyle | Zendy

Open Access

Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase

Author(s) -

Anusha Seneviratne,

Luke Cave,

Gareth Hyde,

Søren K. Moestrup,

David Carling,

Justin C. Mason,

Dorian O. Haskard,

Joseph J. Boyle

Publication year - 2020

Publication title -

cardiovascular research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.774

H-Index - 219

eISSN - 1755-3245

pISSN - 0008-6363

DOI - 10.1093/cvr/cvaa171

Subject(s) - metformin , ampk , medicine , endocrinology , gene knockdown , haematopoiesis , cancer research , protein kinase a , biology , microbiology and biotechnology , diabetes mellitus , kinase , apoptosis , stem cell , biochemistry

Atherosclerotic vascular disease has an inflammatory pathogenesis. Heme from intraplaque haemorrhage may drive a protective and pro-resolving macrophage M2-like phenotype, Mhem, via AMPK and activating transcription factor 1 (ATF1). The antidiabetic drug metformin may also activate AMPK-dependent signalling. Hypothesis: Metformin systematically induces atheroprotective genes in macrophages via AMPK and ATF1, thereby suppresses atherogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research